Are Peptides Legal in Connecticut? (2026)

The federal rules that apply in Connecticut, as everywhere

Federal law is the same in every state, and it is where almost all of the legal weight sits. Under the Federal Food, Drug, and Cosmetic Act a product intended to treat a condition or change how the body works is a drug, and an unapproved new drug cannot be introduced into interstate commerce. That rule binds the seller, not the buyer. The FDA's 2026 warning letters to research-peptide vendors say the same thing eleven times over: a "research use only" label does not help when the website, the bundled bacteriostatic water or a dosing calculator shows the product is meant for human use. The Bureau's enforcement tracker lists every letter, case and lawsuit with its source.

Three federal points matter for a reader in Connecticut:

• Human growth hormone is the exception. 21 U.S.C. § 333(e) makes it a federal offence to distribute or possess somatropin for any use not approved by the Secretary of HHS. That statute covers HGH itself, not the secretagogues (sermorelin, ipamorelin, CJC-1295) that prompt the body's own release.
• Compounding is a separate track. A licensed pharmacy may only compound from bulk substances on the FDA's 503A list. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon were moved to Category 2 in September 2023, removed from it in April 2026, and recommended for the list by the FDA's advisory committee on 23 and 24 July 2026. No rule has followed as of September 2026, so they still cannot be legally compounded anywhere, including Connecticut. The PCAC vote page has every tally.
• GLP-1 compounding is closing, not opening. The FDA has declared the semaglutide and tirzepatide shortages over, proposed in April 2026 to keep both off the 503B bulks list, and sent batches of letters to telehealth sellers in March and June 2026. Vials sold as "GLP-1 S" or "GLP-3 R" for research are unapproved new drugs in the FDA's view wherever the buyer lives.

What Connecticut law adds

Connecticut's controlled-substances law (Conn. Gen. Stat. § 21a-240 et seq. (Dependency-Producing Drugs); schedules in Regs. Conn. State Agencies §§ 21a-243-7 to 21a-243-11; penalties at §§ 21a-277 and 21a-279) decides whether possessing a compound is a state offence. Peptides only become a state-law problem if they appear in those schedules or in a specific state ban. (portal.ct.gov)

Compounds Connecticut has scheduled or restricted

• Chorionic gonadotropin (hCG), Schedule III (Regs. Conn. State Agencies § 21a-243-9; possession § 21a-279(c)) (portal.ct.gov)

Human growth hormone

Human growth hormone does not appear in Connecticut's controlled drug schedules. Chorionic gonadotropin (hCG) is listed as a Schedule III hormone, with sale under § 21a-277(b) and possession under § 21a-279(c). (Department of Consumer Protection controlled drug schedule list) (portal.ct.gov)

Compounded semaglutide and tirzepatide

No Connecticut Board of Pharmacy statement specific to compounded GLP-1 drugs was located. Licensed Connecticut pharmacies follow the federal 503A and 503B rules, under which the shortage exception for semaglutide and tirzepatide has ended.

Clinics, medspas and prescribers

No Connecticut medical board guidance specific to peptide therapy was located. A Connecticut prescriber who administers BPC-157 or another unapproved peptide is exposed under the state's medical practice act and, since the FDA's 2026 letters, under federal law; the July 2026 advisory vote has not changed that yet.

Buying, possessing and using research peptides in Connecticut

No Connecticut provision on possessing unscheduled research peptides was found, so the federal rules apply; hCG is a Connecticut Schedule III drug and unprescribed possession violates § 21a-279(c). (portal.ct.gov)

Ordering from a vendor in another state. Almost every research-peptide order into Connecticut is interstate commerce, which is exactly what the FDCA governs. The risk sits with the vendor: the FDA's letters name the seller, and Eli Lilly said in August 2026 it had referred more than 200 sellers to the FDA, the DOJ, state attorneys general and licensing boards. Connecticut's attorney general has already used state consumer-protection law against a "research grade" GLP-1 seller (2025), which is the template other states can copy. The Bureau's vendor scorecard notes which vendors publish batch testing; none of the scored vendors appears in the tracker as of September 2026.

GLP-1 drugs by prescription. Yes. Conn. Gen. Stat. § 19a-906 holds telehealth to the in-person standard of care and allows physical-examination elements through peripheral devices; the bar on prescribing Schedule I to III controlled substances by telehealth does not affect GLP-1s. (codes.findlaw.com) The branded pens are the only fully approved route; compounded versions are now on the wrong side of the FDA's shortage rules.

Sports and employment testing are not a Connecticut law question. Growth hormone secretagogues and GHRH analogues are on the WADA Prohibited List everywhere; a standard workplace panel does not screen for peptides. The national legal guide covers both.

Enforcement in Connecticut

• 2025-05-21. Attorney General William Tong sent warning letters under the Connecticut Unfair Trade Practices Act to weight-loss clinics, medspas and practices still advertising or prescribing compounded semaglutide and tirzepatide after the shortage ended. (portal.ct.gov)
• 2025-05-21. The attorney general sued Florida-based Triggered Brand for selling research-grade semaglutide and tirzepatide to consumers without prescriptions, under CUTPA and the unlicensed pharmacy practice rules, and issued a civil investigative demand to the Made-in-China marketplace. (portal.ct.gov)
• 2025-08-05. Triggered Brand settled: all sales to cease, with a $300,000 judgment suspended after an $18,500 payment. (portal.ct.gov)
• 2026-05-06. The Made-in-China platform agreed to stop all research-grade GLP-1 sales into the United States and to monitor and remove listings within five days, with a $300,000 penalty suspended after $30,000. (portal.ct.gov)

A warning letter, lawsuit or board complaint is an allegation by the body that issued it, not a court finding, unless the entry says otherwise.

Editor's note. Connecticut is the most active state against research-grade GLP-1 sellers; the legal theory is consumer-protection law plus unlicensed pharmacy practice, not scheduling. A 2026 proposed regulation updating the schedules exists and could not be opened; check whether it touches hCG or peptides.

Frequently asked questions

Is BPC-157 legal in Connecticut?

Connecticut has not scheduled BPC-157, so possessing it is not a Connecticut offence. Federally it is an unapproved new drug: selling it for human use is a violation by the seller, and licensed pharmacies cannot compound it because it is not on the 503A bulks list, despite the advisory committee's July 2026 recommendation. Research vendors sell it under a research-use-only label, which the FDA's 2026 letters treat as no defence when the site shows human use.

Can I get semaglutide or tirzepatide by telehealth in Connecticut?

Yes. Conn. Gen. Stat. § 19a-906 holds telehealth to the in-person standard of care and allows physical-examination elements through peripheral devices; the bar on prescribing Schedule I to III controlled substances by telehealth does not affect GLP-1s. Compounded versions are no longer covered by the FDA's shortage exception, and the FDA has proposed keeping semaglutide and tirzepatide off the 503B bulks list, so expect availability of compounded product to keep shrinking.

Is HGH legal in Connecticut?

Only with a valid prescription for an approved use. Connecticut does not schedule it separately, but federal law, 21 U.S.C. section 333(e), makes distribution or possession for any non-approved use a federal offence. Sermorelin, ipamorelin and CJC-1295 are not HGH and fall under the general unapproved-drug rules instead.

Sources

• https://portal.ct.gov/-/media/dcp/drug_control/pdf/controlleddrugschedulesviolationspenaltiespdf.pdf
• https://codes.findlaw.com/ct/title-19a-public-health-and-well-being/ct-gen-st-sect-19a-906/
• https://portal.ct.gov/-/media/ag/press_releases/2025/letter-to-wt-loss-clinics--spas-52125-final.pdf
• https://portal.ct.gov/ag/press-releases/2025-press-releases/attorney-general-tong-sues-glp-1-weight-loss-drug-distributor-triggered-brand
• https://portal.ct.gov/ag/press-releases/2025-press-releases/bootleg-weight-loss-drug-distributor-to-cease-unlawful-sales-in-settlement-with-state
• https://portal.ct.gov/ag/press-releases/2026-press-releases/attorney-general-tong-announces-online-platform-to-cease-bootleg-weight-loss-drug-sales

Every Connecticut fact above was checked against the linked source on 28 September 2026. If a statute or board position has changed, email [email protected] with the link and the page will be corrected and dated.